Biome Australia Limited

Equities

BIO

AU0000184137

Pharmaceuticals

Market Closed - Australian S.E. 01:12:56 2024-04-26 am EDT 5-day change 1st Jan Change
0.325 AUD +1.56% Intraday chart for Biome Australia Limited -7.14% +58.54%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Biome Australia Logs 74% Revenue Increase in Fiscal Q3 MT
Biome Australia Logs First Positive Underlying Quarterly Cash Flow in Fiscal Q3 MT
Biome Australia Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Biome's Activated Probiotics Enters UK, Ireland; Shares Jump 10% MT
Biome Australia Raises Fiscal 2024 Revenue Guidance MT
Microbiome Health Company Biome Australia Limited Revises Earnings Guidance for 2024 CI
Biome Reports Surge in Half Year Sales Revenue MT
Biome Australia Limited Reports Unaudited Revenue Results for the Second Quarter and Half Year of 2024 CI
Australian Shares Slide as Rate Cut Hopes Lose Steam MT
Biome Australia to Launch Cholesterol-Lowering Probiotic; Shares Climb 6% MT
4,262,808 Options of Biome Australia Limited are subject to a Lock-Up Agreement Ending on 30-NOV-2023. CI
39,359,545 Ordinary Shares of Biome Australia Limited are subject to a Lock-Up Agreement Ending on 30-NOV-2023. CI
Biome Australia Limited Reaffirms Revenue Guidance for the Full Year of Fiscal 2024 CI
Biome Australia Limited Reports Sales Results for the First Five Months Ended November 2023 CI
Biome Australia Sees Higher Sales in Fiscal Year 2024 MT
Biome Australia Limited Provides Sales Revenue Guidance for the Fiscal Year 2024 CI
Biome Australia Logs Record Q1 Sales MT
Biome Australia Limited Announces Unaudited Sales Results for the First Quarter Ended September 2023 CI
Biome Australia Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Biome Australia Adds to Probiotic Range with Product Launch MT
Biome Australia Limited Provides Update on Biome Lift Probiotic Clinical Trial CI
Biome Australia Records 75% Jump in Fiscal 2023 Revenue; Shares Up 4% MT
Biome Australia Limited Reports Unaudited Sales Results for the Fourth Quarter and Full Year of 2023 CI
Biome Australia Jumps 16% After Exceeding FY23 Sales Revenue Target MT
Biome Australia Signs Corporate Advisory Mandate With Boutique Investment Manager MT
Chart Biome Australia Limited
More charts
Biome Australia Ltd is an Australia-based microbiome health company. The Company develops, licenses, commercializes and markets evidence-based live biotherapeutics (probiotics) and complementary medicines. It develops, manufactures, and distributes evidence-based products linking the gut and human health through the Company owned brands, such as Activated Nutrients and Activated Probiotics. Activated Nutrients offers a range of completely organic, plant-based, all in-one nutritional products. Activated Probiotics offers a range of clinically backed precision probiotics. Activated Probiotics provides live biotherapeutic products clinically proven to help prevent and support the management of various health concerns, including low mood and sleep, bone health, iron malabsorption, mild eczema through randomized double-blind placebo-controlled trials. Activated Probiotics products include Biome Acne Probiotic, Biome Baby Probiotic, Biome Eczema Probiotic, and Biome Acne Probiotic.
More about the company

Chiffre d''affaires - Rate of surprise

  1. Stock Market
  2. Equities
  3. BIO Stock
  4. News Biome Australia Limited
  5. Biome Australia Raises Fiscal 2024 Revenue Guidance